ArticleBritish journal of cancer2020
Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank.
Article in British journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Lipoprotein(a) and Prostate Cancer: A Systematic Review of Observational, Genetic and Mendelian Randomization Evidence.International journal of molecular sciences · 2026Pooled it
- Plasma total cholesterol concentration and risk of higher-grade prostate cancer: A nested case-control study and a dose-response meta-analysis.International journal of cancer · 2023Pooled it
- Circulating lipoprotein (a) and all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis.European journal of epidemiology · 2023Pooled it
- Effect of Inorganic Phosphorus Manipulation on the Growth and Progression of Prostate Cancer Cells In Vitro.International journal of molecular sciences · 2025Article
- NCAPD3-mediated AKT activation regulates prostate cancer progression.FASEB bioAdvances · 2025Article
- Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study.Scientific reports · 2025Article
- Severe obesity, high inflammation, insulin resistance with risks of all-cause mortality and all-site cancers, and potential modification by healthy lifestyles.Scientific reports · 2025Article
- Investigating causal relationships of blood and urine biomarkers with urological cancer risks: a mendelian randomization study and colocalization analyses.Journal of Cancer · 2025Article
- Article
- Stacked neural network for predicting polygenic risk score.Scientific reports · 2024Article
- Associations of serum cystatin C concentrations with total mortality and mortality of 12 site-specific cancers.Frontiers in molecular biosciences · 2024Article
- Liver Fibrosis Scores and Prostate Cancer Risk and Mortality in the Atherosclerosis Risk in Communities Study.Cancer prevention research (Philadelphia, Pa.) · 2023Article
- Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study.The Prostate · 2023Article
- Clinical biomarker-based biological aging and risk of cancer in the UK Biobank.British journal of cancer · 2023Article
- Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4-20 ng/mL.Scientific reports · 2022Article
- The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study.PLoS medicine · 2022Article
- Role of cystatin C in urogenital malignancy.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundAlthough prostate cancer is a leading cause of cancer death, its aetiology is not well understood. We aimed to identify novel biochemical factors for prostate cancer incidence and mortality in UK Biobank.
methodsA range of cardiovascular, bone, joint, diabetes, renal and liver-related biomarkers were measured in baseline blood samples collected from up to 211,754 men at recruitment and in a subsample 5 years later. Participants were followed-up via linkage to health administrative datasets to identify prostate cancer cases. Hazard ratios (HRs) and 95% confidence intervals were calculated using multivariable-adjusted Cox regression corrected for regression dilution bias. Multiple testing was accounted for by using a false discovery rate controlling procedure.
resultsAfter an average follow-up of 6.9 years, 5763 prostate cancer cases and 331 prostate cancer deaths were ascertained. Prostate cancer incidence was positively associated with circulating vitamin D, urea and phosphate concentrations and inversely associated with glucose, total protein and aspartate aminotransferase. Phosphate and cystatin-C were the only biomarkers positively and inversely, respectively, associated with risk in analyses excluding the first 4 years of follow-up. There was little evidence of associations with prostate cancer death.
conclusionWe found novel associations of several biomarkers with prostate cancer incidence. Future research will examine associations by tumour characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.